To clarify different effects of daily and weekly hPTH(1-34), teriparatide, administration on local and systemic bone metabolism during healing period after vertebral fracture.
Not Applicable
- Conditions
- osteoporosis
- Registration Number
- JPRN-UMIN000008610
- Lead Sponsor
- Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients in whom study drugs (teriparatide) are contraindicated 2. Serious renal, hepatic, or cardiac disease 3. Secondly osteoporosis 4. Patients who are considered inappropriate for enrollment by the investigator for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone metabolic markers
- Secondary Outcome Measures
Name Time Method Vertebral and femoral bone mineral density, numbers of new vertebral fractures during the study period, VAS, JOQOL, RDQ, QUEST, and bony union